Reply to Second malignancies in Ewing sarcoma survivors
Cancer
.
2017 Oct 15;123(20):4075-4076.
doi: 10.1002/cncr.30921.
Epub 2017 Aug 24.
Authors
Neyssa M Marina
1
,
Qi Liu
2
,
Sarah S Donaldson
3
,
Charles A Sklar
4
,
Gregory T Armstrong
5
,
Kevin C Oeffinger
4
,
Wendy M Leisenring
6
,
Jill P Ginsberg
7
,
Tara O Henderson
8
,
Joseph P Neglia
9
,
Marilyn A Stovall
10
,
Yutaka Yasui
5
,
R Lor Randall
11
,
David S Geller
12
,
Leslie L Robison
5
,
Kirsten K Ness
5
Affiliations
1
Five Prime Therapeutics, Two Corporate Drive, South San Francisco, California.
2
School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
3
Department of Radiation Oncology, Stanford University, Stanford, California.
4
Department of Medicine, Duke Cancer Institute, Durham, North Carolina.
5
Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
6
Seattle Children's Hospital, Clinical Statistics, Seattle, Washington.
7
Department of Pediatric Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
8
Pediatric Oncology, Comprehensive Cancer Center, University of Chicago, Chicago, Illinois.
9
Department of Pediatrics, University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota.
10
Houston, Texas.
11
Department of Orthopedic Surgery, Primary Children's Hospital and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
12
Montefiore Medical Center-Moses Campus and Orthopedic Surgery, Children's Hospital at Montefiore, Bronx, New York.
PMID:
28837220
PMCID:
PMC5626614
DOI:
10.1002/cncr.30921
No abstract available
Publication types
Letter
Research Support, N.I.H., Extramural
Comment
MeSH terms
Bone Neoplasms*
Humans
Neoplasms, Second Primary*
Sarcoma, Ewing*
Survivors
Grants and funding
U24 CA055727/CA/NCI NIH HHS/United States